奥佳华智能健康科技集团股份有限公司 独立董事提名人声明 提名人奥佳华智能健康科技集团股份有限公司董事会现就提名王志强为奥 佳华智能健康科技集团股份有限公司第六届董事会独立董事候选人发表公开声 明。被提名人已书面同意出任奥佳华智能健康科技集团股份有限公司第六届董事 会独立董事候选人。本次提名是在充分了解被提名人职业、教育背景、专业资格、 工作经历、全部兼职等情况后作出的，本提名人认为被提名人符合相关法律、行 政法规、部门规章、规范性文件和深圳证券交易所业务规则对独立董事候选人任 职资格及独立性的要求，具体声明并承诺如下事项： 一、被提名人已经通过奥佳华智能健康科技集团股份有限公司第五届董事会 提名委员会资格审查（如适用），提名人与被提名人不存在利害关系或者可能妨 碍被提名人独立履职的其他关系。 √ 是 □ 否 二、被提名人不存在《中华人民共和国公司法》第一百四十六条等规定不得 担任公司董事的情形。 √ 是 □ 否 三、被提名人符合中国证监会《上市公司独立董事管理办法》和深圳证券交 易所自律监管规则规定的独立董事任职资格和条件。 √ 是 □ 否 四、被提名人符合公司章程规定的独立董事任职条件。 八、被提名人担任独 ...

奥佳华智能健康科技集团股份有限公司 独立董事提名人声明 提名人奥佳华智能健康科技集团股份有限公司董事会现就提名蔡天智为奥 佳华智能健康科技集团股份有限公司第六届董事会独立董事候选人发表公开声 明。被提名人已书面同意出任奥佳华智能健康科技集团股份有限公司第六届董事 会独立董事候选人。本次提名是在充分了解被提名人职业、教育背景、专业资格、 工作经历、全部兼职等情况后作出的，本提名人认为被提名人符合相关法律、行 政法规、部门规章、规范性文件和深圳证券交易所业务规则对独立董事候选人任 职资格及独立性的要求，具体声明并承诺如下事项： 一、被提名人已经通过奥佳华智能健康科技集团股份有限公司第五届董事会 提名委员会资格审查（如适用），提名人与被提名人不存在利害关系或者可能妨 碍被提名人独立履职的其他关系。 √ 是 □ 否 二、被提名人不存在《中华人民共和国公司法》第一百四十六条等规定不得 担任公司董事的情形。 √ 是 □ 否 三、被提名人符合中国证监会《上市公司独立董事管理办法》和深圳证券交 易所自律监管规则规定的独立董事任职资格和条件。 √ 是 □ 否 四、被提名人符合公司章程规定的独立董事任职条件。 √ 是 □ 否 六 ...

奥佳华智能健康科技集团股份有限公司 独立董事候选人声明 声明人曹阳，作为奥佳华智能健康科技集团股份有限公司第六届董事会独立 董事候选人，现公开声明和保证，本人与该公司之间不存在任何影响本人独立性 的关系，且符合相关法律、行政法规、部门规章、规范性文件和深圳证券交易所 业务规则对独立董事候选人任职资格及独立性的要求，具体声明并承诺如下事项： 一、本人已经通过奥佳华智能健康科技集团股份有限公司第五届董事会提名 委员会资格审查（如适用），提名人与本人不存在利害关系或者可能妨碍本人独 立履职的其他关系。 √ 是 □ 否 二、本人不存在《中华人民共和国公司法》第一百四十六条等规定不得担任 公司董事的情形。 √ 是 □ 否 三、本人符合中国证监会《上市公司独立董事管理办法》和深圳证券交易所 业务规则规定的独立董事任职资格和条件。 √ 是 □ 否 四、本人符合该公司章程规定的独立董事任职条件。 √ 是 □ 否 五、本人已经参加培训并取得证券交易所认可的相关培训证明材料（如有）。 √ 是 □ 否 六、本人担任独立董事不会违反《中华人民共和国公务员法》的相关规定。 √ 是 □ 否 七、本人担任独立董事不会违反中共中央纪委《关于 ...

经核查，我们认为：本次公司董事会换届选举的非独立董事、独立董事候 选人提名已征得被提名人本人同意，提名、表决程序符合相关法律法规和《公 司章程》的规定。经审查董事候选人的履历等材料，不存在《公司法》和《公 司章程》规定的不得担任公司董事、独立董事的情形，也未有被中国证监会确 定为市场禁入者且禁入尚未解除的情况，其任职资格符合担任上市公司董事的 条件，其教育背景、任职经历、专业能力和职业素养能够胜任所聘任的职位。 我们同意提名邹剑寒先生、李五令先生、陈淑美女士、林建华先生、肖婷 婷女士、郭桃花女士为公司非独立董事候选人；同意提名蔡天智先生、曹阳先 生、王志强先生为公司独立董事候选人。并同意将上述事项提请公司 2023 年第 二次临时股东大会审议。 奥佳华智能健康科技集团股份有限公司独立董事 关于公司第五届董事会第二十一次会议相关事项的独立意见 根据中国证监会《上市公司独立董事规则》、《深圳证券交易所股票上市规 则》、《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运 作》及公司章程等有关法律、法规的规定，作为奥佳华智能健康科技集团股份 有限公司（以下简称"公司"）的独立董事，我们就公司于 20 ...

奥佳华智能健康科技集团股份有限公司 独立董事提名人声明 提名人奥佳华智能健康科技集团股份有限公司董事会现就提名曹阳为奥佳 华智能健康科技集团股份有限公司第六届董事会独立董事候选人发表公开声明。 被提名人已书面同意出任奥佳华智能健康科技集团股份有限公司第六届董事会 独立董事候选人。本次提名是在充分了解被提名人职业、教育背景、专业资格、 工作经历、全部兼职等情况后作出的，本提名人认为被提名人符合相关法律、行 政法规、部门规章、规范性文件和深圳证券交易所业务规则对独立董事候选人任 职资格及独立性的要求，具体声明并承诺如下事项： 一、被提名人已经通过奥佳华智能健康科技集团股份有限公司第五届董事会 提名委员会资格审查（如适用），提名人与被提名人不存在利害关系或者可能妨 碍被提名人独立履职的其他关系。 √ 是 □ 否 二、被提名人不存在《中华人民共和国公司法》第一百四十六条等规定不得 担任公司董事的情形。 √ 是 □ 否 三、被提名人符合中国证监会《上市公司独立董事管理办法》和深圳证券交 易所自律监管规则规定的独立董事任职资格和条件。 √ 是 □ 否 四、被提名人符合公司章程规定的独立董事任职条件。 五、被提名人已经参加 ...

√ 是 □ 否 四、本人符合该公司章程规定的独立董事任职条件。 奥佳华智能健康科技集团股份有限公司 独立董事候选人声明 声明人蔡天智，作为奥佳华智能健康科技集团股份有限公司第六届董事会独 立董事候选人，现公开声明和保证，本人与该公司之间不存在任何影响本人独立 性的关系，且符合相关法律、行政法规、部门规章、规范性文件和深圳证券交易 所业务规则对独立董事候选人任职资格及独立性的要求，具体声明并承诺如下事 项： 一、本人已经通过奥佳华智能健康科技集团股份有限公司第五届董事会提名 委员会资格审查（如适用），提名人与本人不存在利害关系或者可能妨碍本人独 立履职的其他关系。 √ 是 □ 否 二、本人不存在《中华人民共和国公司法》第一百四十六条等规定不得担任 公司董事的情形。 √ 是 □ 否 三、本人符合中国证监会《上市公司独立董事管理办法》和深圳证券交易所 业务规则规定的独立董事任职资格和条件。 √ 是 □ 否 八、本人担任独立董事不会违反中共中央组织部《关于进一步规范党政领导 干部在企业兼职（任职）问题的意见》的相关规定。 √ 是 □ 否 九、本人担任独立董事不会违反中共中央纪委、教育部、监察部《关于加强 高等学校反腐 ...

证券代码：002614 股票简称：奥佳华 公告编号：2023-21 号 债券代码：128097 债券简称：奥佳转债 奥佳华智能健康科技集团股份有限公司 关于参加厦门辖区上市公司 2023 年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，奥佳华智能健康科技集团股份有限公司 （以下简称"公司"）将参加由厦门证监局、厦门上市公司协会与深圳市全景网 络有限公司联合举办的"2023 年厦门辖区上市公司投资者集体接待日活动"，现 将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登陆"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参与 本次互动交流，活动时间为 2023 年 5 月 12 日（星期五）下午 14:30-16:15。届 时公司董事长兼总经理邹剑寒先生，副总经理兼董事会秘书李巧巧女士，财务总 监苏卫标先生将在线就公司 2022 年度业绩、公司治理、经营状况和发展战略等 投资者关心的问题，与投资者进行沟通与交流，欢迎广大 ...

Financial Performance - The company's revenue for Q1 2023 was ¥1,182,959,019.74, a decrease of 25.30% compared to ¥1,583,603,294.78 in the same period last year[5] - Net profit attributable to shareholders was ¥19,158,027.94, down 30.81% from ¥27,687,468.03 year-on-year[5] - The company's basic earnings per share decreased by 25.00% to ¥0.03 from ¥0.04 in the same period last year[5] - Total operating revenue for Q1 2023 was ¥1,182,959,019.74, a decrease of 25.2% compared to ¥1,583,603,294.78 in the same period last year[23] - Net profit for Q1 2023 was ¥19,590,153.69, a decline of 19.8% from ¥24,220,336.23 in Q1 2022[25] - Other comprehensive income after tax for Q1 2023 was ¥12,422,925.82, compared to ¥17,176,185.57 in the same period last year[25] - The total comprehensive income for Q1 2023 was ¥32,013,079.51, a decrease from ¥41,396,521.80 in Q1 2022[26] Cash Flow - The net cash flow from operating activities increased by 386.44%, reaching ¥79,880,543.46, compared to a negative cash flow of -¥27,887,419.95 in Q1 2022[14] - Cash flow from operating activities generated a net amount of ¥79,880,543.46, a significant improvement from a net outflow of ¥27,887,419.95 in Q1 2022[28] - The net cash flow from financing activities for Q1 2023 was -266,663,076.22 CNY, compared to 103,835,960.11 CNY in the same period last year[29] - The net increase in cash and cash equivalents for Q1 2023 was -423,893,423.72 CNY, while it was 95,307,169.85 CNY in Q1 2022[29] - The cash and cash equivalents at the beginning of Q1 2023 were 1,286,580,012.95 CNY, compared to 1,141,248,144.29 CNY at the beginning of Q1 2022[29] - The cash and cash equivalents at the end of Q1 2023 were 862,686,589.23 CNY, down from 1,236,555,314.14 CNY at the end of Q1 2022[29] Assets and Liabilities - Total assets decreased by 6.07% to ¥8,179,426,287.77 from ¥8,707,784,113.72 at the end of the previous year[5] - The company’s total liabilities decreased by 6.07%, reflecting a strategic focus on debt repayment and financial management[5] - Total liabilities decreased to CNY 3,324,189,953.04 from CNY 3,888,434,934.46, a reduction of approximately 14.5%[21] - The company's total equity remained stable at CNY 4,855,236,334.73, with a slight increase from CNY 4,819,349,179.26[21] - Current assets decreased to CNY 5,235,995,254.70 from CNY 5,734,442,867.62, reflecting a decline of approximately 8.7%[18] - Cash and cash equivalents decreased to CNY 885,950,905.62 from CNY 1,320,167,493.56, a drop of about 33%[18] - Inventory levels decreased to CNY 1,058,595,784.49 from CNY 1,171,098,532.66, indicating a decline of about 9.6%[20] - The company reported accounts receivable of CNY 695,688,337.48, down from CNY 832,352,343.62, a decrease of approximately 16.4%[18] - The company’s long-term investments slightly decreased to CNY 67,663,358.94 from CNY 68,437,732.37[20] Operating Costs and Expenses - The company experienced a 36.89% reduction in operating costs, which amounted to ¥711,363,564.91, down from ¥1,127,118,460.01 year-on-year[11] - Total operating costs for Q1 2023 were ¥1,171,748,132.14, down 27.0% from ¥1,605,296,749.75 year-over-year[23] - Research and development expenses for Q1 2023 were ¥49,646,461.22, down 22.1% from ¥63,821,842.75 in Q1 2022[23] Other Income and Investments - The company reported a significant increase in other income, which rose by 30.30% to ¥10,686,530.86 compared to ¥8,201,462.22 in Q1 2022[12] - The company’s investment income showed a significant decline, with a loss of ¥5,622,688.91 compared to a profit of ¥43,313,092.10 in the same period last year, marking a 112.98% decrease[12] Reporting and Audit - The Q1 2023 report was not audited[30] - The report was presented by the Board of Directors on April 26, 2023[31]

Financial Performance - The company's operating revenue for 2022 was CNY 6,024,336,706.63, a decrease of 24.00% compared to CNY 7,926,722,192.23 in 2021[22] - The net profit attributable to shareholders for 2022 was CNY 102,022,883.31, down 77.74% from CNY 458,358,173.45 in the previous year[22] - Basic earnings per share for 2022 were CNY 0.16, a decline of 78.38% from CNY 0.74 in 2021[23] - The company reported a diluted earnings per share of CNY 0.18 for 2022, down 73.53% from CNY 0.68 in 2021[23] - The weighted average return on equity for 2022 was 2.16%, a decrease of 7.73% from 9.89% in 2021[23] - The total assets at the end of 2022 were CNY 8,707,784,113.72, a decrease of 6.01% from CNY 9,264,966,121.78 at the end of 2021[23] - The net assets attributable to shareholders decreased by 3.55% to CNY 4,657,466,510.02 from CNY 4,828,764,373.98 in 2021[23] Cash Flow and Investments - The net cash flow from operating activities increased significantly to CNY 742,083,023.25, a 4336.37% increase from a negative cash flow of CNY -17,516,934.66 in 2021[22] - The total cash inflow from financing activities rose by 24.42% to 1,017,531,582.05 CNY, reflecting an increase in financing through notes payable[73] - The total investment cash outflow increased by 55.42% to 727,762,745.25 CNY, indicating a rise in capital expenditures[73] - The company reported a significant decrease in the cost of goods sold, with a total of 3,986,171,108.13 CNY, down from 5,379,597,842.08 CNY in 2021[63] - The company has invested RMB 43,500,000 in structured deposits and seven-day notice deposits from the raised funds[93] Revenue Segmentation - The main business revenue accounted for ¥5.89 billion, representing 97.69% of total revenue, down 23.71% from ¥7.71 billion in 2021[58] - Revenue from the health massage segment was ¥4.44 billion, which is 75.41% of total revenue, a decline of 19.26% from ¥5.50 billion in 2021[58] - The company's health massage business revenue accounted for 75.41% of total revenue, an increase of 4.15% year-on-year[41] - The sales volume of massage chairs decreased by 15.78% to 395,900 units in 2022 from 470,100 units in 2021[61] Product Development and Innovation - The company achieved a research and development investment of 247 million CNY during the reporting period, accumulating a total of 1,356 patents[38] - The flagship product featuring the fifth-generation 4D brushless variable frequency temperature-sensing core has shown outstanding performance in AI intelligence and user experience[49] - The company launched a series of high-margin new products and adjusted the pricing of main products to stabilize market share despite a significant decline in overall market demand[37] - The company is focusing on core business areas and enhancing its brand through continuous innovation and marketing efforts to adapt to market changes[33] Market Challenges and Strategies - The overall economic environment in 2022 posed significant challenges, with global demand for health massage products declining due to various geopolitical and economic factors[32] - The company faces risks from macroeconomic fluctuations, which could impact demand for its massage products[108] - The company is exposed to exchange rate fluctuations, particularly with revenues primarily in foreign currencies[109] - The company is at risk from raw material and shipping price volatility, which could affect profitability[110] Corporate Governance and Management - The company strictly adheres to relevant laws and regulations, continuously improving its corporate governance structure and internal control systems[115] - The company operates independently from its controlling shareholders, with no significant related party transactions or competition with them[116] - The company has established an independent financial department, ensuring complete control over its financial decisions and tax obligations[118] - The company has a diverse management team with backgrounds in various fields, including finance, management, and technology[127] Shareholder Returns and Dividends - The company plans to distribute a cash dividend of CNY 3 per 10 shares to all shareholders[5] - The cash dividend distribution plan includes a payout of RMB 3.00 per 10 shares (tax included), amounting to a total cash dividend of RMB 187,040,793.00, which represents 100% of the profit distribution total[150][151] - The company has continuously implemented cash dividends for 11 years since its listing, ensuring the legitimate rights and interests of shareholders[160] Social Responsibility and Community Engagement - The company has donated a total of RMB 3.12 million in love materials to various organizations, including nearly HKD 1.5 million in donations from its subsidiary medisana[163] - The company has actively participated in rural revitalization projects, contributing over RMB 500,000 for poverty alleviation and disaster relief efforts[164] - The company emphasizes employee well-being by providing annual health check-ups and creating a fitness-friendly environment[161] Risk Management - The company has established a risk management organization to supervise and evaluate its internal control management[153] - The internal control audit report confirmed that the company maintained effective financial reporting internal controls as of December 31, 2022[157] - There were no significant defects identified in the internal control system during the reporting period[157]